Medical device regulatory readiness in Brazil (ANVISA)
Brazil is Latin America’s largest medical-device market, regulated by ANVISA.
In Short
- Regulator: Agência Nacional de Vigilância Sanitária (ANVISA) oversees medical devices across premarket, manufacturing, importation, distribution, and post-market…
- Brazil adopts a risk-based GHTF-style classification under RDC 751/2022: Class I (low), Class II (moderate), Class III (high), and Class IV (highest).
- Pathways under RDC 751/2022: - Cadastro (Class I–II): Simplified route.
Since 2022, Brazil has modernized its framework, replacing RDC 185/2001 with RDC 751/2022 for device classification, essential safety and performance requirements, and registration rules, and updating Good Manufacturing Practices via RDC 665/2022 with explicit alignment to ISO 13485 and acceptance of MDSAP evidence. Manufacturers must appoint a Brazilian Registration Holder (BRH), navigate Cadastro (Class I–II) or Registro (Class III–IV), and, for electromedical devices, obtain INMETRO certification to NBR IEC 60601 series. Post-market tecnovigilância, Portuguese labeling, and a UDI framework under development complete the compliance picture. This guide distills what RA/QA leaders need to get to market and stay compliant in Brazil.
1) The regulator and the legal framework
Regulator: Agência Nacional de Vigilância Sanitária (ANVISA) oversees medical devices across premarket, manufacturing, importation, distribution, and post-market surveillance (tecnovigilância). Legal basis draws from Law No.
More on 1) The regulator and the legal framework
9.782/1999 (establishes ANVISA) and subsequent sectoral RDCs (Resoluções da Diretoria Colegiada). Key instruments (last major revisions): - RDC 751/2022: Core framework for classification, essential safety and performance requirements (ESPR), documentation, and approval pathways; supersedes RDC 185/2001 for devices (non-IVD). Annexes adopt GHTF-based rules and define the technical dossier structure. - RDC 665/2022: Good Manufacturing Practices (GMP/CBPF) procedures aligned to ISO 13485; enables use of MDSAP certificates as evidence for granting/maintaining Brazilian GMP (CBPF), with ANVISA discretion for inspections. - INMETRO Ordinances and conformity programs: Mandatory certification for specified product families (e.g., electromedical) to ABNT NBR IEC 60601 series via OCPs (Organismos de Certificação de Produto) accredited by Inmetro. - RDC 431/2020: Instructions for Use (IFU) and labeling, including provisions for electronic IFU (e-IFU) in defined circumstances. - Tecnovigilância framework: RDC 67/2009 and ANVISA guidance detail adverse event reporting (via Notivisa), field actions, and complaint handling. Other operational systems: Peticionamento eletrônico through Portal Solicita/Datavisa for submissions and tracking. Foreign manufacturers must operate via a Brazilian Registration Holder (BRH), a local legal entity with AFE (Autorização de Funcionamento de Empresa) authorization.
2) Device classification in Brazil (Class I–IV)
Brazil adopts a risk-based GHTF-style classification under RDC 751/2022: Class I (low), Class II (moderate), Class III (high), and Class IV (highest). Classification rules in Annex I consider intended use, contact duration and invasiveness, energy source, and whether the device sustains/supports life.
More on 2) Device classification in Brazil (Class I–IV)
Key drivers: - Invasiveness and duration (transient, short-term, long-term) - Active vs non-active and whether it administers/withdraws energy or substances - Implantability and life-support/life-sustaining claims - Use with medicinal products or blood/fluids - Sterility, measuring function, and reusability aspects Classification dictates the pathway: generally Cadastro for Class I and II, and Registro for Class III and IV. Certain special categories (e.g., electromedical, sterile, measuring) may impose additional testing and certification (e.g., INMETRO) regardless of the base class. Borderline and accessory determinations follow intended purpose statements; ANVISA may be petitioned for clarification when classification is ambiguous. Your classification also drives expectations for clinical evidence depth, technovigilância controls, and labeling particulars (e.g., serial/UDI readiness). Maintain a defensible rationale that maps each applicable rule to your risk outcome.
3) Conformity assessment and approval pathways (Cadastro vs Registro)
Pathways under RDC 751/2022: - Cadastro (Class I–II): Simplified route. Class I is typically notified with immediate grant upon complete electronic filing; Class II undergoes documentary review.
More on 3) Conformity assessment and approval pathways (Cadastro vs Registro)
Both require a technical dossier maintained by the BRH/manufacturer, available to ANVISA upon request. - Registro (Class III–IV): Full scientific-technical review. Requires comprehensive dossier, including clinical evidence where applicable. Core dossier content for both (depth increases for Registro): - Administrative: BRH authorization (AFE, CNPJ), powers of attorney for foreign manufacturers, applicant/manufacturer details, manufacturing sites, and fee proof. - Device description and intended use; variants/accessories; materials; sterilization and shelf-life (ISO 11135/11137/17665 as applicable); biocompatibility (ABNT NBR ISO 10993 series); electrical safety/EMC (ABNT NBR IEC 60601-1/-1-2) or relevant standards; software lifecycle for SaMD/SiMD (IEC 62304; see /glossary/iec-62304); usability (IEC 62366) when applicable. - Conformity to Essential Safety and Performance Requirements (ESPR) checklist per RDC 751/2022. - Risk management (ISO 14971) and benefit-risk summary. - Clinical evaluation/clinical investigation data for novel/high-risk technologies (Registro), aligned to GHTF/IMDRF principles; foreign clinical data are acceptable if applicable to the Brazilian population and context. - INMETRO: For electromedical and other designated products, provide valid Inmetro OCP certification and test reports to ABNT NBR standards before approval and commercialization. - GMP/CBPF: Evidence per RDC 665/2022—ANVISA-issued CBPF certificate or MDSAP certificate accepted to grant/maintain CBPF; ANVISA may still inspect. Submission mechanics: Peticionamento eletrônico via Portal Solicita.
4) QMS and GMP expectations (RDC 665/2022 and ISO 13485/MDSAP)
RDC 665/2022 updates Brazil’s GMP (CBPF) program to align closely with ISO 13485 and the MDSAP audit model. Manufacturers must demonstrate an effective QMS covering design/development, production, servicing, purchasing, traceability (where applicable), complaint handling, corrective/preventive actions, and post-market surveillance.
More on 4) QMS and GMP expectations (RDC 665/2022 and ISO 13485/MDSAP)
Key points: - MDSAP acceptance: ANVISA accepts valid MDSAP certificates issued by recognized Auditing Organizations as evidence to grant or maintain CBPF for the certified scope. ANVISA retains discretion to conduct inspections. - Scope accuracy: Ensure all manufacturing sites (including sterilizers, critical suppliers, and software development sites for SaMD) are within the certified scope. Misaligned scopes trigger deficiencies. - BRH integration: The BRH must maintain procedures for distribution, vigilance, and recalls; interfaces with the foreign manufacturer’s QMS should be defined contractually and procedurally. - Records: Maintain DMR/DHR, validation (processes, software used in production/quality), equipment calibration, environmental controls, and training records in Portuguese or with certified translations for inspection. - MDSAP modules mapping: Leverage the MDSAP Brazil country-specific requirements (including tecnovigilância and labeling controls) to prepare for CBPF and inspections without surprises.
5) UDI, labeling, and Portuguese language requirements
Labeling and IFU: RDC 431/2020 sets requirements for labeling and instructions for use. Content must be in Brazilian Portuguese, including device name/model, manufacturer and BRH (name, address, CNPJ), ANVISA approval number (Cadastro or Registro), lot/serial number, manufacturing/expiry dates (where applicable), storage conditions, single-use/sterility status, warnings/precautions, and importer details for imported products.
More on 5) UDI, labeling, and Portuguese language requirements
Electromedical products must bear the INMETRO conformity mark once certified. E‑IFU is permitted for certain professional-use devices under defined risk controls; lay-use and many implantables still require paper IFU. UDI: ANVISA is developing a UDI framework aligned with IMDRF principles (device identifier on label and submission of core data to an ANVISA UDI database). While final RDC and timelines are pending, manufacturers should prepare to encode a Basic UDI-DI-like identifier and production identifiers, maintain master data, and ensure label/packaging space and data governance are UDI-ready. Translations: All end-user content must be in Portuguese; technical files may be in English but ANVISA can request Portuguese translations of critical sections. Consistency between IFU, labeling, and the dossier is scrutinized.
6) Post-market surveillance (tecnovigilância), complaints, and reporting
Brazil’s tecnovigilância system obligates manufacturers/BRHs to monitor device performance, collect/analyze complaints, and report adverse events and field actions to ANVISA via Notivisa. Core expectations: - Complaint handling: Maintain processes to log, investigate, trend, and close complaints; determine reportability per Brazilian criteria. - Reporting timelines: Serious adverse events (death or serious deterioration in health) typically require initial notification within 10 calendar days; other reportable incidents within 30 calendar days.
More on 6) Post-market surveillance (tecnovigilância), complaints, and reporting
Provide follow-up and a final investigation report when available; ANVISA may set case-specific deadlines. - Field Safety Corrective Actions (Ações de Campo): Notify ANVISA promptly, implement corrections/recalls, and communicate to users/distributors in Portuguese; submit effectiveness checks and closure reports. - PMS plans: For higher-risk or novel devices, maintain proactive PMS methods (surveys, PMCF-like activities, literature review) supporting ongoing benefit–risk. - BRH role: The BRH is the local focal point for Notivisa submissions, coordination with healthcare services, and stock recovery. Keep distribution traceability sufficient to execute targeted field actions. Deficiency patterns include late reporting, incomplete root cause/CAPA, and inconsistent labeling claims vs IFU/usability evidence.
7) A 90–180 day readiness plan for Brazil market entry
- Days 0–30
Strategy and classification - Appoint/select a Brazilian Registration Holder (BRH) with AFE; execute technical and vigilance responsibilities in the contract. - Classify the device under RDC 751/2022; confirm pathway (Cadastro vs Registro); identify if INMETRO applies (electromedical, etc.). - Gap assess QMS to RDC 665/2022 and MDSAP; confirm site scopes; plan to leverage MDSAP for CBPF. - Start Portuguese labeling/IFU authoring; define claims consistent with dossier.
- Days 31–60
Evidence assembly and certification kickoff - Compile ESPR checklist; finalize risk management (ISO 14971) and V&V matrices; confirm biocompatibility/sterilization evidence. - If applicable, engage an Inmetro-accredited OCP; submit product samples and CB reports; schedule any factory audit; typical cycle 6–10 weeks. - For SaMD/active devices, finalize IEC 62304 and 60601-1/-1-2 evidence. - Build the Brazil technical dossier (Cadastro or Registro depth) and translation plan; load administrative documents (BRH AFE/CNPJ, powers of attorney).
- Days 61–90
Submission and GMP alignment - File peticionamento eletrônico via Portal Solicita; include INMETRO certificate or furnish proof of ongoing certification if ANVISA allows staged submission (verify case-by-case). - If needed, request CBPF based on MDSAP; respond to any ANVISA scheduling/data requests. - Stand up tecnovigilância SOPs and Notivisa access for the BRH; train distribution partners.
- Days 91–180
Review, responses, and launch prep - Manage ANVISA exigências within deadlines; maintain a single-source dossier for updates. - Complete INMETRO and affix the conformity mark; finalize Portuguese labeling with ANVISA/Registro number once granted. - Validate distribution and recall traceability; rehearse field action communication temp.
Questions
How long does ANVISA approval take for each class?
Class I devices are typically granted upon electronic notification when filings are complete. Class II (Cadastro) reviews commonly take 2–6 months. Class III–IV (Registro) are usually 9–15 months, driven by dossier complexity, clinical evidence, and queue. If ANVISA requires a GMP (CBPF) inspection rather than accepting MDSAP, add several months; leveraging a valid MDSAP certificate often shortens the critical path.
Do I need a Brazilian legal representative or Registration Holder (BRH)? What are the costs?
Yes. Foreign manufacturers must appoint a Brazilian Registration Holder (BRH)—a local legal entity with AFE authorization and CNPJ—to hold the Cadastro/Registro, submit to ANVISA, manage tecnovigilância/recalls, and ensure Portuguese labeling. Government fees (TFVS) apply per petition and for GMP certification; INMETRO certification involves OCP and testing fees; BRH services are commercial agreements. Exact costs depend on device class, number of models, testing needs, and company size (fee reductions may apply to SMEs).
Does ANVISA accept MDSAP instead of a Brazilian GMP inspection?
Under RDC 665/2022, ANVISA accepts a valid MDSAP certificate from a recognized Auditing Organization as evidence to grant or maintain Brazilian GMP (CBPF) for the certified scope. ANVISA may still perform inspections at its discretion (e.g., for new technologies, complaints, or scope gaps). Ensure all sites (including critical suppliers/sterilizers) are covered by the MDSAP scope you submit.
Are FDA 510(k) or CE marks recognized for faster approval?
ANVISA does not grant automatic recognition of FDA or CE approvals. However, underlying evidence (bench tests, biocompatibility, clinical data) generated to internationally recognized standards, and MDSAP/ISO 13485 certificates, are acceptable and can support your Brazil dossier. For electromedical devices, INMETRO certification to ABNT NBR IEC 60601 series is mandatory regardless of FDA/CE status.
What are common reasons ANVISA rejects or delays applications?
Frequent issues include: incorrect risk classification; missing or expired INMETRO certificates for electromedical devices; inconsistent Portuguese labeling/IFU vs the technical dossier; insufficient clinical or risk-benefit justification for high-risk devices; gaps in GMP scope (sites not covered) when using MDSAP; incomplete ESPR checklist; and weak complaint/vigilance procedures for the BRH. Early gap assessment and precise translations help avoid exigências.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Medical Device Production Guide
Built to revision. Inspected. On record.
- What the QMSR changed in February 2026
- Supplier to finished build
- Inspect, review, correct
- Labels, UDI and traceability
Plus Evidence map and four worksheets.
Get the medical device guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Medical Device Production Guide
Built to revision. Inspected. On record.
Keep reading
- Global medical device regulatory readiness (2026)
Australia Medical Device Regulatory Readiness Guide
Canada Medical Devices Regulations (SOR/98-282) Readiness
China Medical Device Regulatory Readiness Guide 2026
EU MDR medical device regulatory readiness (European Union)
GCC Medical Device Readiness: Saudi Arabia & UAE